Ad hoc announcement pursuant to Article 53 LR26 February 2026 – 06:30 AMThe Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics across regions and technologies. The global automotive market is growing at a low single-digit rate, while shifts in climate policy and subsidy schemes – particularly in the United States – are influencing investment decisions and the pace of electrification. At the same time, demand for in ...

In 2025, Inbank’s consolidated net profit increased to €19.2 million, up 57% year-on-year. Return on equity (ROE) improved to 12.3% for the full year. In Q4 2025, Inbank earned a net profit of €6.1 million, increasing 339% year-on-year, and ROE for Q4 reached 14.7%. In 2025, total net income reached €85.1 million, increasing 13% year-on-year, while operating expenses remained broadly flat at €46.3 million. As a result, net profit increased 57% to €19.2 million and return on equity improved to 12.3%. The co ...

CGTN published an article on German Chancellor Friedrich Merz's official visit to China from February 25 to 26. The article highlights the significance of the visit and analyzes – from economic and political perspectives – how China and Germany have written a successful story of win-win cooperation, and how their partnership injects stability into China-Europe relations and global governance. BEIJING, Feb. 25, 2026 (GLOBE NEWSWIRE) -- German automaker BMW announced plans in April 2025 to start integrating a ...

Core Viewpoint - InnoCare Pharma has made significant progress in clinical development, completing patient enrollment in multiple Phase III registrational trials for its cancer and autoimmune disease treatments [1] Group 1: Clinical Development Progress - The company completed patient enrollment in a Phase III trial for the BCL2 inhibitor mesutoclax (ICP-248) combined with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients [2] - InnoCare has also accelerated the clinical development of two novel TYK2 inhibitors, completing patient enrollment in the Phase III trial of soficitinib (ICP-332) for moderate to severe atopic dermatitis and in the Phase III trial of ICP-488 for psoriasis [4] - Additionally, patient enrollment has been completed in a Phase II trial of soficitinib for vitiligo, targeting various T-cell related autoimmune disorders [5] Group 2: Drug Mechanisms and Indications - Mesutoclax is a selective oral BCL2 inhibitor that restores normal apoptosis in cancer cells, aiming to provide deeper remission for treatment-naïve CLL/SLL patients [3] - Soficitinib is a potent TYK2 inhibitor being developed for multiple dermatological conditions, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and psoriasis [5][6] - ICP-488, an oral allosteric TYK2 inhibitor, blocks inflammatory cytokine signaling pathways, addressing autoimmune and inflammatory diseases [6] Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [7]

Core Insights - DMG Blockchain Solutions Inc. reported its fiscal first quarter 2026 unaudited financial results, highlighting a focus on its core data center operations and digital asset financial services [1][3] Financial Performance - Revenue for Q1 2026 was $11.2 million, a decrease of 4% from $11.6 million in Q1 2025, primarily due to a $1.8 million drop in digital currency mining revenues, partially offset by $1.5 million from energy efficiency incentives [4][10] - Operating and maintenance expenses remained stable at $6.7 million, while general and administrative costs slightly increased to $1.9 million due to higher consulting fees related to AI strategy investments [5] - Depreciation expenses decreased to $3.5 million from $4.3 million in Q1 2025, reflecting the declining balance depreciation method [6] - The net loss for Q1 2026 was $2.2 million, an improvement from a net loss of $3.1 million in Q1 2025, attributed to reduced operating losses and foreign exchange impacts [7] - Comprehensive income/loss showed a significant decline, moving from a gain of $12.2 million in Q1 2025 to a loss of $16.5 million in Q1 2026, mainly due to unrealized valuation losses on digital currency [8] Asset and Cash Position - Total assets as of December 31, 2025, were $122.0 million, down from $132.0 million at the end of September 2025, driven by a $6.0 million decrease in digital asset valuations and $3.1 million in fixed asset depreciation [9][10] - Cash, short-term investments, and digital assets totaled $58.6 million at the end of Q1 2026, a decrease of 10% from $65.2 million at year-end 2025 [10] Operational Highlights - The company mined 69 bitcoins in Q1 2026, down from 97 bitcoins in Q1 2025, while the hashrate increased by 10% to 1.76 EH/s [10] - DMG is converting its Christina Lake facility into an AI data center with a capacity of at least 50 megawatts, aiming to fill an industry gap in available capacity [3] Future Outlook - The company is actively pursuing AI off-takers and potential government partnerships to drive future revenue growth through its Systemic Trust initiative [3]

Core Insights - The vaping industry continues to evolve with new product formats, yet high-performance mods like VOOPOO's DRAG series remain popular among seasoned vapers [1] - The upcoming DRAG 6 is set to launch in March 2026, featuring significant innovations such as the GENE TT 3.0 chip and the UFORCE-X Tank II [2] Group 1: Product Highlights - VOOPOO's DRAG 5 was recognized as the "Best Vape Mod" in 2024 and continues to lead the market two years later [1] - The DRAG series has a history of technological advancements, including instant-inhaling capabilities and rapid igniting speeds, with the DRAG 6 expected to continue this legacy [2] Group 2: Marketing and Promotions - VOOPOO has initiated an Early Bird event offering 50% OFF vouchers and a chance to win 166 free DRAG 6 coupons, encouraging community engagement [3] - The company will showcase the DRAG 6 at Vapexpo Paris 2026 and TPE26 in March, allowing users to experience the product firsthand [3]

Core Insights - MindRank has initiated the Phase III clinical trial for MDR-001, an AI-designed oral GLP-1 receptor agonist aimed at treating obesity and type 2 diabetes in China [1][2] - The trial, named MOBILE, will involve approximately 750 patients across 50 clinical centers, assessing the long-term efficacy and safety of MDR-001 [2] - MDR-001 has shown promising results in a Phase IIb trial, demonstrating clinically meaningful efficacy and favorable tolerability [3] Company Overview - MindRank is a clinical-stage biotechnology company that leverages AI for drug discovery, focusing on "hard-to-drug" targets to enhance the efficiency and success rate of new drug development [9] - The company utilizes its proprietary AI platform, Molecule Pro™, which integrates various scientific disciplines to optimize drug discovery processes [7][9] Technology and Innovation - The Molecule Pro™ platform employs advanced AI techniques, including deep learning and generative AI, to facilitate drug discovery and optimize lead compounds [7][8] - The platform's capabilities include predicting drug safety and optimizing molecular design to improve the chances of successful drug development [8] Development Milestones - The development of MDR-001 progressed from project initiation to U.S. IND clearance in 19 months and reached Phase III within approximately 4.5 years [4] - The dosing of the first patient in Phase III is considered a significant milestone for both MDR-001 and AI-driven drug development [6]

Core Insights - Paul Mueller Company and Springfield Public Schools have launched a Welding and Grinding Registered Youth Apprenticeship partnership, marking a significant advancement in workforce development for advanced manufacturing in Missouri [1][9] - This initiative is the only stainless welding and grinding pathway in Missouri, creating a direct link between classroom education and paid industry experience [2][9] Company Overview - Paul Mueller Company is recognized as one of the largest and most innovative stainless steel manufacturers globally, with over 85 years of experience in manufacturing [2] - The company specializes in designing and manufacturing stainless steel processing equipment and heat transfer solutions for various markets, including food, beverage, dairy, pharmaceutical, chemical, nuclear, and industrial sectors [6] Apprenticeship Program Details - The apprenticeship program allows students aged 17 and above to earn up to $25 per hour while gaining hands-on experience in stainless steel welding and grinding, along with earning educational credits [4] - The program follows a nationally recognized Registered Apprenticeship model, emphasizing paid employment, structured on-the-job learning, industry-aligned training, and portable credentials [4] Community Impact - The partnership aims to create meaningful opportunities for students and strengthen the skilled workforce in southwest Missouri, reflecting a commitment to community investment and operational excellence [5] - This initiative is expected to build a sustainable talent pipeline that supports both student success and regional economic strength [5]

Core Viewpoint - Draganfly Inc. has announced a registered direct offering of 7,150,000 common shares at a price of US$7.00, aiming for gross proceeds of approximately US$50.0 million before expenses [1]. Group 1: Offering Details - The offering is being led by Maxim Group LLC, with Raymond James Ltd. and Ladenburg Thalmann & Co. Inc. as co-placement agents [2]. - The expected closing date for the offering is around February 27, 2026, pending customary closing conditions [3]. - The offering is subject to regulatory approvals from the Canadian Securities Exchange and notification to the Nasdaq Stock Market [4]. Group 2: Use of Proceeds - Draganfly intends to utilize the net proceeds for general corporate purposes, including funding new product capabilities, growth initiatives, working capital, and ongoing development and marketing of core products [3]. Group 3: Regulatory Compliance - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission and the Company's Canadian short form base shelf prospectus [5]. - A prospectus supplement will be filed with relevant securities commissions in Canada and the SEC in the U.S. [6]. Group 4: Company Overview - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in various sectors including public safety, agriculture, and industrial inspections [8].

Company Overview - TRG Latin America Acquisitions Corp. is a blank check company incorporated in the Cayman Islands, formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [4] - The company intends to leverage the expertise of its management team, particularly focusing on identifying a target business that can benefit from the experience of its CEO and Chairman Nicolas S. Rohatyn and CFO Miguel A. Gutierrez [5] Initial Public Offering (IPO) Details - The company has priced its initial public offering at $10.00 per unit, with a total of 20,000,000 units being offered [1] - The units will be listed on the Nasdaq Stock Exchange under the ticker symbol "TRGSU" starting February 26, 2026, and will consist of one Class A ordinary share and one right entitling the holder to receive one-tenth of one Class A ordinary share upon the completion of a business combination [1] - The offering includes a 45-day option for the underwriter, Santander, to purchase up to an additional 3,000,000 units at the IPO price to cover over-allotments [2] - The offering is expected to close on February 27, 2026, subject to customary closing conditions [3] Management and Board Members - The management team includes Nicolas S. Rohatyn as CEO and Chairman, and Miguel A. Gutierrez as CFO, both of whom are co-founders and partners at The Rohatyn Group [5] - The board of directors will include Miguel Kiguel, Daniel Gerold, and Thomas Wolf [6]